<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765647</url>
  </required_header>
  <id_info>
    <org_study_id>AGY</org_study_id>
    <nct_id>NCT01765647</nct_id>
  </id_info>
  <brief_title>Oral AGY for Celiac Disease</brief_title>
  <official_title>Use of an Orally Administered Antibody to Gluten to Prevent the Recurrence of Symptoms and Laboratory Parameters in Persons With Celiac Disease (Gluten Sensitive Enteropathy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igy Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Igy Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Celiac disease (CD) is an autoimmune disease of the small intestine caused by the consumption
      of gluten proteins from widely used food sources such as wheat, rye, and barley. Exposure of
      the small intestine to gluten causes an inflammatory response, leading to the destruction of
      intestine lining, often with severe symptoms including diarrhea, abdominal distention,
      fatigue, weight loss, anemia, and neurological symptoms. CD is a lifelong disease and the
      only treatment currently available is strict adherence to a life-time gluten free diet (GFD).
      However, adhering to this diet is difficult as gluten proteins are found in many food
      products. Therefore, the gluten-free diet has both lifestyle and financial implications for
      the individual and thus has been potential for impacting adversely on their quality of life.

      Various approaches are being studied to reduce the need for careful control of the diet for
      those with CD, including the use of antibodies such as IgY. IgY is produced from the egg
      yolks of super immunized laying hens. Egg yolk antibodies are natural products with minimal
      toxicity, for those without egg allergy, and offer low-cost, hygienic production of study
      product. Once the IgY antibody is put into capsule form, it is called AGY.

      Individuals with CD will be recruited only if they have a history of biopsy proven CD,
      currently follow a GFD but continue to have mild to moderate symptoms related to gluten
      exposure, and do not have an egg allergy. Blood will be tested for ATG antibody levels at
      screening. Those enrolled will have a 2 week run-in period where diet and symptoms are
      recorded, and will then receive AGY capsules to take with meals over a 4 week period.
      Outcomes will be measured by examining lab test results including antibody levels, symptoms,
      and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will last approximately 6 weeks. Individuals will be screened to ensure they are
      following a gluten free diet, continue to have mild to moderate symptoms of gluten exposure
      despite the diet, and have a history of biopsy proven celiac disease. Those meeting this
      criteria will then have a baseline visit which will include a short physical exam and
      additional lab work for safety measures, and quality of life questionnaires. They will record
      their diet and symptoms for 2 weeks, and then return to receive the study medication, which
      will be taken with all meals. The first dose will be taken in clinic to facilitate
      observation of any adverse effects. The next visit will be 2 weeks later for blood work and
      clinic visit, and then again 2 weeks later for the final visit. Participants will be prompted
      to report any adverse events that occur during the trial period and at the completion of the
      trial. During the trial period, the study coordinator will phone participants to remind them
      to complete their questionnaires and to inquire about adverse events. All participants will
      receive AGY capsules (500 mg per capsule), and will take 2 capsules with each meal.

      Outcome measures The primary outcome variable will be the safety (adverse events, lab
      results, symptoms), which will be measured throughout the study.

      The secondary outcome will be ATG antibody levels, which will be measured at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants received open label AGY, a natural health product</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants for Which Treatment Was Concluded to be Safe</measure>
    <time_frame>week 6</time_frame>
    <description>Measures include: adverse events, serious adverse events, withdrawal due to adverse events, abnormal lab results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Celiac Disease Related Symptoms in Participants</measure>
    <time_frame>daily for 6 weeks</time_frame>
    <description>Symptoms of Celiac disease will be self-measured by participants daily for the entire 6 week study period using the Celiac Symptom Index tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>week 6</time_frame>
    <description>health related quality of life will be measured at 4 time points using a validated tool; (short form 36; SF-36) baseline, week 2, week 4, and at the end of the study at week 6.
Scores can range from 20-80, with 50 being a population norm. Therefore, a score above 50 indicates better than the general population norm, and a score below 50 indicates worse than the population norm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ATG Antibody Level</measure>
    <time_frame>screening through final visit</time_frame>
    <description>The ATG antibody level will be measured at baseline, week 2, week 4 and week 6. Normal values are less than 7; elevated values mean a worse outcome. Assessed at baseline, week 2, week 4 and week 6; baseline and week 6 reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>AGY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive the same, open-label dose of AGY</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AGY</intervention_name>
    <description>AGY is a natural health product produced in egg yolks</description>
    <arm_group_label>AGY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or over

          -  confirmed diagnosis of Celiac disease by previous biopsy

          -  follow a gluten-free diet (GFD)

          -  have mild to moderate symptoms despite the GFD diet

        Exclusion Criteria:

          -  diabetic

          -  use of steroids in previous year

          -  current use of ASA/NSAIDs, metronidazole, or misoprostol

          -  excess alcohol intake

          -  egg allergy

          -  history of severe complications of celiac disease or chronic active GI disease

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Dieleman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <results_first_submitted>October 15, 2018</results_first_submitted>
  <results_first_submitted_qc>November 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2019</results_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Celiac disease</keyword>
  <keyword>AGY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
          <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">One began the run-in period, but was withdrawn prior to beginning treatment with AGY</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">10 entered the AGY treatment phase and all 10 completed treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
          <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" lower_limit="29" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants for Which Treatment Was Concluded to be Safe</title>
        <description>Measures include: adverse events, serious adverse events, withdrawal due to adverse events, abnormal lab results</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
            <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants for Which Treatment Was Concluded to be Safe</title>
          <description>Measures include: adverse events, serious adverse events, withdrawal due to adverse events, abnormal lab results</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mild adverse events during run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate adverse events during run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe adverse events during run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild adverse events on tx week 2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate adverse events on tx week 2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe adverse events on tx week 2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild adverse events on tx week 4-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate adverse events on tx week 4-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe adverse events on tx week 4-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse events at any time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>withdrawal due to adverse event at any time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>all cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Celiac Disease Related Symptoms in Participants</title>
        <description>Symptoms of Celiac disease will be self-measured by participants daily for the entire 6 week study period using the Celiac Symptom Index tool.</description>
        <time_frame>daily for 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
            <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
          </group>
        </group_list>
        <measure>
          <title>Number Celiac Disease Related Symptoms in Participants</title>
          <description>Symptoms of Celiac disease will be self-measured by participants daily for the entire 6 week study period using the Celiac Symptom Index tool.</description>
          <units>Number of Celiac Disease Related Symptom</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tiredness during 2 weeks of run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tiredness during last 2 weeks on AGY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache during 2 weeks of run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache during last 2 weeks on AGY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>abdominal pain/discomfort during 2 weeks of run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>abdominal pain/discomfort during last 2 weeks on A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bloating during 2 weeks of run-in</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bloating during last 2 weeks on AGY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life</title>
        <description>health related quality of life will be measured at 4 time points using a validated tool; (short form 36; SF-36) baseline, week 2, week 4, and at the end of the study at week 6.
Scores can range from 20-80, with 50 being a population norm. Therefore, a score above 50 indicates better than the general population norm, and a score below 50 indicates worse than the population norm.</description>
        <time_frame>week 6</time_frame>
        <population>Scores were assessed at baseline, week 2, week 4 and week 6; baseline and week 6 reported.</population>
        <group_list>
          <group group_id="O1">
            <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
            <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life</title>
          <description>health related quality of life will be measured at 4 time points using a validated tool; (short form 36; SF-36) baseline, week 2, week 4, and at the end of the study at week 6.
Scores can range from 20-80, with 50 being a population norm. Therefore, a score above 50 indicates better than the general population norm, and a score below 50 indicates worse than the population norm.</description>
          <population>Scores were assessed at baseline, week 2, week 4 and week 6; baseline and week 6 reported.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline physical component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.08" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 physical component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.77" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline mental component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.34" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 mental component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.12" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ATG Antibody Level</title>
        <description>The ATG antibody level will be measured at baseline, week 2, week 4 and week 6. Normal values are less than 7; elevated values mean a worse outcome. Assessed at baseline, week 2, week 4 and week 6; baseline and week 6 reported.</description>
        <time_frame>screening through final visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
            <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
          </group>
        </group_list>
        <measure>
          <title>ATG Antibody Level</title>
          <description>The ATG antibody level will be measured at baseline, week 2, week 4 and week 6. Normal values are less than 7; elevated values mean a worse outcome. Assessed at baseline, week 2, week 4 and week 6; baseline and week 6 reported.</description>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline IgA TTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="1.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 IgA TTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.922" spread="0.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AGY: Anti-gliadin Antibody for Celiac Disease</title>
          <description>All participants will receive the same, open-label dose of AGY
AGY: AGY is a natural health product produced in egg yolks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>sore ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>itchy or red eyes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>tiredness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>sphincter of oddi syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cold symptoms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>menstrual cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>conjestion or sore throat</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dory Sample</name_or_title>
      <organization>University of Alberta</organization>
      <phone>780-248-5599</phone>
      <email>dory.sample@ahs.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

